美国疑似环肽蕈类中毒当前病死率
本研究为2008年1月1日至2018年12月31日对美国国家毒物数据系统(NPDS)报告的疑似含环肽蕈类摄入病例的11年回顾性分析,纳入标准与正在进行的开放标签水飞蓟宾试验相同:年龄>2岁、有采食野生蘑菇史、摄入后48小时内出现胃肠道症状、摄入后48小时内转氨酶高于正常上限。研究期间NPDS共报告8953例蘑菇暴露,296例符合纳入标准,经毒物控制中心确认和排除后最终纳入148例。总病死率为8.8%(13/148);水飞蓟宾/水飞蓟素治疗组病死率为9.5%(4/42),未治疗组为8.5%(9/106)。真菌学家鉴定出蘑菇的病例占16.9%(25/148),其中80%(20/25)含环肽;在这些确诊病例中,治疗组和未治疗组的病死率均为10%(1/10)。作者认为,这一当代病死率(8.8%)可能反映了急性肝损伤支持治疗的改善,应作为美国历史对照的当前标准。
要点
- 美国NPDS 2008-2018年疑似含环肽蕈类摄入并符合纳入标准者总病死率为8.8%(13/148),远低于常被引用的>20%未治疗病死率。
- 水飞蓟宾/水飞蓟素治疗组病死率为9.5%(4/42),未治疗组为8.5%(9/106),两组数值接近。
- 真菌学家鉴定出蘑菇的病例占16.9%(25/148),其中80%(20/25)含环肽;确诊病例中治疗组和未治疗组病死率均为10%(1/10)。
- 作者认为8.8%的病死率可能反映了急性肝损伤支持治疗的改善,应作为美国历史对照的当前标准。
适用人群与场景
- 年龄>2岁、有采食野生蘑菇史、摄入后48小时内出现胃肠道症状、摄入后48小时内转氨酶高于正常上限的疑似含环肽蕈类摄入患者,数据来自美国国家毒物数据系统(NPDS)2008年1月1日至2018年12月31日报告病例。
诊断标准与关键阈值
- 纳入标准与正在进行的开放标签水飞蓟宾试验相同:年龄>2岁;有采食野生蘑菇史;摄入后48小时内出现胃肠道症状;摄入后48小时内转氨酶高于正常上限。
研究设计与关键结果
- 研究类型为11年(2008年1月1日至2018年12月31日)回顾性分析,数据来自美国国家毒物数据系统(NPDS),共报告8953例蘑菇暴露,296例符合纳入标准,经毒物控制中心确认和排除后最终纳入148例。
- 总病死率为8.8%(13/148);水飞蓟宾/水飞蓟素治疗组病死率为9.5%(4/42),未治疗组为8.5%(9/106)。
- 真菌学家鉴定出蘑菇的病例占16.9%(25/148),其中80%(20/25)含环肽;在这些确诊病例中,水飞蓟宾/水飞蓟素治疗组和未治疗组的病死率均为10%(1/10)。
- 毒物控制中心调查应答率为60%(28/47),个体病例应答率为59%(174/296),随后排除26例,最终纳入148例。
证据类型、等级与局限
- 证据类型为回顾性分析;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,疑似环肽蕈类中毒的当代病死率仅为8.8%,这可能反映了急性肝损伤支持治疗的改善,应作为美国历史对照的当前标准。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This study was designed to determine the fatality rate of suspected cyclopeptide-containing mushroom ingestions reported to the National Poison Data System (NPDS).
BACKGROUND: Although silibinin reportedly improves survival in suspected cyclopeptide-containing mushroom ingestions, the greater than 20% untreated fatality rate that is often cited is based on decades-old data. An ongoing open-label silibinin trial will likely use historical cases as comparators. A recent single poison control center (PCC) study showed a fatality rate of 8.3%. This study was designed to validate those findings in the NPDS.
METHODS: This study was an 11-year (1/1/2008-12/31/2018) retrospective review of suspected cyclopeptide-containing mushroom ingestions reported to NPDS. Inclusion and exclusion criteria were the same as the ongoing silibinin trial: Age >2-years-old; history of eating foraged mushrooms; gastrointestinal symptoms within 48 h of mushroom ingestion; and aminotransferases above the upper limit of normal within 48 h after ingestion. Each original participating PCC confirmed eligibility, diagnosis, treatment, and outcome on included cases.
RESULTS: During the study period, 8,953 mushroom exposures were reported to NPDS, of which 296 met inclusion criteria. The PCC survey response rate was 60% (28/47 PCCs), and the individual case response rate was 59% (174/296). Twenty-six cases were subsequently excluded leaving 148 included cases. The overall mortality rate was 8.8% (13/148). Mortality in silibinin/silymarin-treated vs untreated cases was 9.5% (4/42), vs 8.5% (9/106), respectively. A mycologist identified mushrooms in 16.9% of cases (25/148), of which 80% (20/25) were cyclopeptide-containing. Among these confirmed cases, the mortality rate was 10% (1/10) in both silibinin/silymarin-treated and untreated cases.
CONCLUSIONS: The contemporary mortality rate of patients with presumed cyclopeptide-mushroom poisoning is only 8.8%. This likely represents improved supportive care for patients with acute liver injury and should be considered the current standard for historical controls in the United States.
参考来源
- De Olano J, Wang JJ, Villeneuve E, et al. Current fatality rate of suspected cyclopeptide mushroom poisoning in the United States. Clin Toxicol (Phila). 2020. PMID: 32237919. doi:10.1080/15563650.2020.1747624
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。